0.00Open0.00Pre Close0 Volume0 Open Interest90.00Strike Price0.00Turnover0.00%IV-188.83%PremiumMay 16, 2025Expiry Date58.84Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.54Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Vaxcyte Stock Discussion
Gapping Up
$Corcept Therapeutics (CORT.US)$ surged over 60% after the company announced that its Phase 3 trial, ROSELLA, met its primary endpoint, improving progression-free survival in platinum-resistant ovarian cancer patients.
$QuantaSing Group (QSG.US)$ surged 20.18% in pre-market trading following a 12% increase on Friday. Last week, QuantaSing Group expanded into the pop toys market through the strategic acqui...
Breakthrough: Vaxcyte's New Vaccine Shows Promise in Phase 2 Infant Trial
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$